State-of-the-Art Cancer Biology, Biodiagnostics and Therapeutics in Japan

Yamaguchi J, di Luccio E, Hirotsu T
Biomedicines · 2023 · vol. 11(11) · doi:10.3390/biomedicines11112905 · PMID:38001906 · PMC10669596
Review OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-23 ⓘ

This paper reviews state-of-the-art cancer biology, biodiagnostics, and therapeutics in Japan to improve early detection, patient survival, quality of life, and financial outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-14 · read from full text ⓘ

This review article outlines the current landscape of cancer biology, biodiagnostics, and therapeutics within Japan. It details advancements in oncological research and clinical applications specific to the Japanese healthcare system and scientific community. The text serves as a broad overview of the state-of-the-art developments in these fields without focusing on a single disease entity or specific patient population. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Early cancer detection is key to improving patient survival and quality of life and reducing cancer treatments' financial burden [...].
Full text 660 characters · extracted from epmc-fulltextxml · 3 sections · click to expand

Author

Conceptualization, J.Y.; writing—original draft preparation, J.Y.; writing—review and editing, J.Y., E.d.L. and T.H.; supervision, E.d.L. and T.H. All authors have read and agreed to the published version of the manuscript.

Fn Group

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Conflicts

J.Y., E.d.L. and T.H. are employees of Hirotsu Bio Science Inc.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-25T09:32:14.900964+00:00
pubmed
last seen: 2026-10-08T21:42:03.417289+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC